HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Andreassen, M. Articles by Kristensen, L. O. Search for Related Content PubMed PubMed Citation Articles by Andreassen, M. Articles by Kristensen, L. O.

Rosiglitazone for prevention or adjuvant treatment of Nelson’s syndrome after bilateral adrenalectomy

Department of Endocrinology and Internal Medicine, J 106, Herlev Hospital, University of Copenhagen, Herlev Ringvej, 2730 Herlev, Denmark

(Correspondence should be addressed to M Andreassen; Email: andreassenmikkel{at}hotmail.com)

Abstract

Objective: To investigate the effect of Rosiglitazone in three patients treated with bilateral adrenalectomy followed by hyperpigmentation and hypersecretion of ACTH.

Patients and methods: One patient had increasing ACTH after previous transsphenoidal surgery for Nelson’s syndrome, and two patients without pituitary adenomas had recurrence of Cushing’s disease after primary and repeated transsphenoidal surgery with need for bilateral adrenalectomy. The patients developed hyperpigmentation and increasing ACTH at nadir 2–4 h after morning hydrocortisone dose. ACTH during Rosiglitazone therapy (4 mg/day for 4 weeks and then 8 mg/day) was measured at regular intervals 24 h after the latest dose of hydrocortisone.

Results: In two patients there was a decrease in ACTH by 40% after 5 months. The first of these patients showed an escape with increasing ACTH to the initial value after 11 months. In the third patient no effect was observed. Tumour development or progression on magnetic resonance imaging was not observed.

Conclusion: Rosiglitazone might represent an adjuvant therapy in patients with ACTH hypersecretion. Larger long-term studies are needed.

This article has been cited by other articles:

				A. Munir, F. Song, P. Ince, S. J. Walters, R. Ross, and J. Newell-Price Ineffectiveness of Rosiglitazone Therapy in Nelson's Syndrome J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1758 - 1763. [Abstract] [Full Text] [PDF]